πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

ALMIRALL S.P.A Patents

Full USPTO pharma patent portfolio for ALMIRALL S.P.A β€” grant dates, expiration, and drug cross-links.

Patents
308
Expiring ≀24m
14

Quick answer

ALMIRALL S.P.A has 308 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 14 expire within 24 months β€” use filters for patent-cliff planning.

Page 2 of 7

  1. US 11485738

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11479551

    MTA-cooperative PRMT5 inhibitors

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11453683

    KRas G12D inhibitors

    Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11439532

    Point of delivery cold slurry generation

    Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11426418

    Injectable long-acting semi-solid gel formulations

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11344605

    Therapeutic use of inhibitors of t cell activation or stimulation

    Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11324673

    Cosmetic appearance of skin

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11273132

    Topical dapsone and dapsone/adapalene compositions and methods for use thereof

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11267812

    KRAS G12C inhibitors

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11254739

    Anti-human migration stimulating factor (MSF) and uses thereof

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11220509

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11123399

    Modulators of complement activity

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11116733

    Topical dapsone and dapsone/adaplene compositions and methods for use thereof

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11091495

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11014965

    Modulation of complement activity

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11000409

    Devices and methods for slurry generation

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11000517

    Dosage and formulation

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10954287

    Ras binding peptides and methods of use

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10945503

    Systems, devices and methods for styling hair

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10918691

    Modulators of complement activity

    Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10906871

    Processes for making, and methods of using, glycopyrronium compounds

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10835574

    Modulators of complement activity

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10792370

    Antibody-drug conjugate

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10759793

    2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10689377

    KRas G12C inhibitors

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10676537

    Antibody targeted to tissue factor, preparation method therefor, and use thereof

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10647715

    KRas G12C inhibitors

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10633381

    KRas G12C inhibitors

    Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10588895

    Quinuclidine derivatives and medicinal compositions containing the same

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10588936

    Modulators of complement activity

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10561606

    Injectable long-acting local anesthetic semi-solid gel formulations

    Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10562934

    Modulation of complement activity

    Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10548875

    Glycopyrrolate salts

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10543192

    Glycopyrrolate salts

    Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10500281

    Injectable long-acting local anesthetic semi-solid formulations and its compositions

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10456390

    Combinations comprising MABA compounds and corticosteroids

    Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10435438

    Modulation of complement activity

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10407403

    Preparation method of cobimetinib

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10337005

    Oligonucleotide-based inhibitors comprising locked nucleic acid motif

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10328115

    Modulators of complement activity

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10316318

    Oligonucleotide compositions and uses thereof

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10300072

    Cyclohexylamine derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist activities

    Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10280422

    MiR-92 inhibitors and uses thereof

    Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10278976

    Methods for treating or preventing cancer in a KRAS-variant patient and for diagnosing risk of developing multiple primary breast tumors

    Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10272132

    Peptide and peptidomimetic inhibitors

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10266542

    EZH2 inhibitors

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10233152

    LSD1 inhibitors

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10220093

    Long-acting semi-solid lipid formulations

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does ALMIRALL S.P.A have?

308 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do ALMIRALL S.P.A patents expire?

14 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.